Research topics
Modulation and suppression of antitumour immunity, epigenetic regulations in tumour immunology, HPV16-associated tumours, immunotherapy of MHC class I-positive and -deficient tumours, gene and cell immunotherapy, minimal residual tumour disease.
Current grant support
Grant Agency of the Czech Republic (grants Nos.: 301/07/1410, 301/09/1024)
Academy of Sciences of the Czech Republic (grants Nos.: IAA500520605, IAA500520807)
The European Clinical Gene Transfer Advisory Network (Clinigene, EC-NoE, FP6+7)
Most important recent papers
(2003-present; names of the lab members underlined)Bubenik, J., Mikyskova, R., Vonka, V., Mendoza, L., Simova, J., Smahel, M., Indrova, M.: Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21: 891-6, 2003. (PubMed)
Indrova, M., Bubenik, J., Mikyskova, R., Mendoza, L., Simova, J., Bieblova, J., Jandlova, T., Jinoch, P., Smahel, M., Vonka, V., Pajtasz-Piasecka, E.: Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22: 691-5, 2003. (PubMed)
Mendoza, L., Bubenik, J., Simova, J., Jandlova, T., Vonka, V., Mikyskova, R.: Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int. J. Oncol. 23: 243-7, 2003. (PubMed)
Mikyskova, R., Indrova, M., Simova, J., Jandlova, T., Bieblova, J., Jinoch, P., Bubenik, J., Vonka, V.: Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int. J. Oncol. 24: 161-7, 2004. (PubMed)
Reinis, M., Indrova, M., Mendoza, L., Mikyskova, R., Bieblova, J., Bubenik, J., Simova, J.: HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int. J. Oncol. 25: 1165-70, 2004. (PubMed)
Mikyskova, R., Bubenik, J., Vonka, V., Smahel, M., Indrova, M., Bieblova, J., Simova, J., Jandlova, T.: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int. J. Oncol. 26: 521-7, 2005. (PubMed)
Reinis, M., Simova, J., Bubenik, J.: Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours. Int. J. Cancer. 118: 1836-42, 2006. (PubMed)
Indrova, M., Bieblova, J., Jandlova, T., Vonka, V., Pajtasz-Piasecka, E., Reinis, M.: Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int. J. Oncol. 28: 253-9, 2006. (PubMed)
Simova J, Bubenik J, Bieblova J, Rosalia RA, Fric J, Reinis M. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int . J. Oncol. 29: 1567-71, 2006. (PubMed)
Reinis, M., Weiser, B., Kuiken, C., Dong, T., Lang, D., Nachman, S., Zhang, Y., Rowland-Jones, S., Burger, H.: Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressors. AIDS Res. Hum. Retroviruses. 23: 309-15, 2007. (PubMed)
Reinis M, Simova J, Indrova M, Bieblova J, Pribylova H, Moravcova S,Jandlova T, Bubenik J. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours. Int. J. Oncol. 30: 1011-7, 2007. (PubMed)
Reinis M, Simova J, Indrova M, Bieblova J, Bubenik J. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. Int. J. Oncol. 30: 1247-51, 2007. (PubMed)
Indrova M, Bieblova J, Bubenik J, Reinis M. IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol. 32: 499-507, 2008. (PubMed)
Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J, Reinis M. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology. 123: 218-27, 2008. (PubMed) (FullText)
Indrova M, Bieblova J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubenik J, Reinis M. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol. 34:173-9, 2009. (PubMed)
Kemal KS, Reinis M, Weiser B, Burger H. Methods for Viral RNA Isolation and PCR Amplification for Sequencing of Near Full-Length HIV-1 Genomes. Methods Mol Biol. 485:3-14, 2009. (PubMed)
Reviews
Bubenik, J.: Animal models for development of therapeutic HPV16 vaccines. Int. J. Oncol. 20: 207-12, 2002. (PubMed)
Bubenik, J.: Tumour MHC class I downregulation and immunotherapy. Oncol. Rep. 10: 2005-8, 2003. (PubMed)
Bubenik, J.: MHC class I down-regulation: tumour escape from immunesurveillance? Int. J. Oncol. 25: 487-91, 2004. (PubMed)
Reinis, M.: Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL. Curr. Opin. Mol. Ther. 6: 206-11, 2004. (PubMed)
Bubenik, J., Simova, J.: Minimal residual disease as the target for immunotherapy and gene therapy of cancer. Oncol. Rep. 14: 1377-80, 2005. (PubMed)
Niederhafner P, Reinis M, Sebestík J, Jezek J. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J Pept Sci. 14:556-87, 2008. (PubMed)
Reinis M. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas. Curr Opin Mol Ther.10:526-34, 2008. (PubMed)
Bubenik J. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours. Curr Cancer Drug Targets. 8:180-6, 2008. (PubMed)